LILRA4, also known as ILT7 and CD85g, is an approximately 60-70 kDa variably glycosylated transmembrane protein that regulates immune cell activation. Mature human LILRA4 consists of a 423 amino acid (aa) extracellular domain (ECD) with four immunoglobulin-like domains, a 21 aa transmembrane segment, and a 32 aa cytoplasmic domain. Alternative splicing generates an additional isoform that lacks the signal peptide and a portion of the first Ig-like domain. LILRA4 is expressed on plasmacytoid dendritic cells (pDC) but is down-regulated in response to TLR9 signaling. Antibody mediated crosslinking of LILRA4 on pDC inhibits the production of type I interferons following TLR7 or TLR9 stimulation. It also blocks the up-regulation of CCR7 but enhances the up-regulation of Integrin beta 7 on TLR7/9-stimulated pDC. LILRA4 associates with the ITAM-containing adaptor protein Fc epsilon RI gamma, and this complex binds to cell surface BST2/Tetherin which is expressed on monocytes, plasmacytoid and myeloid dendritic cells, B cells, and activated CD4+ and CD8+ T cells. This interaction inhibits the TLR-induced pDC production of type I interferons, IL-6, and TNF-alpha.

高纯度、高活性、低内毒素、高批间一致性

产品数据
 

-25 ~ -15℃保存，收到货之后有效期1年。 复溶后， 无菌条件下，-85 ~ -65℃保存，3个月有效期。